TG Therapeutics, Inc. (NASDAQ: TGTX) has reported its financial results for the fourth quarter and full year of 2025, along with recent company developments and 2026 financial guidance. The company's total revenue for the fourth quarter of 2025 was $192.6 million and $616.3 million for the full year, including Briumvi U.S. net revenue of $182.7 million and $594.1 million, respectively.
Briumvi, the company's novel monoclonal antibody, reported significant year-over-year growth in the U.S. with a 92% increase in revenue, reaching $594.1 million for the full year of 2025. Furthermore, TG Therapeutics raised its 2026 revenue guidance to approximately $875-900 million in total global revenue, including Briumvi U.S. net product revenue of approximately $825-$850 million.
In terms of expenses, the company completed a $100 million share repurchase program in the third quarter of 2025. Additionally, TG Therapeutics announced board authorization of a new share repurchase program to acquire up to an additional $100 million of the company's common stock.
In terms of financial performance, the company's net income for the fourth quarter of 2025 was $23.0 million and $447.2 million for the full year, compared to $23.3 million and $23.4 million for the same periods in 2024, respectively. The 2025 results include a non-recurring income tax benefit of approximately $339.8 million, driven by the release of the company's deferred tax asset valuation allowance in the third quarter of 2025.
TG Therapeutics also provided updates on its development pipeline, including achieving approximately 75% patient enrollment into the phase 3 pivotal program evaluating subcutaneous ublituximab and completing patient enrollment into the randomized phase 3 pivotal program to evaluate a consolidated day 1 and day 15 dosing regimen for intravenous (IV) Briumvi in the ongoing enhance trial.
The company's cash, cash equivalents, and investment securities were reported at $199.5 million as of December 31, 2025, with an anticipation that this, combined with projected revenues from Briumvi, will be sufficient to fund the business based on its current operating plan.
TG Therapeutics also outlined anticipated milestones for its development pipeline in 2026, including announcing pivotal topline data for the enhance trial combining day 1 and day 15 doses of IV Briumvi mid-year 2026 and presenting preliminary phase 1 azer-cel data in progressive MS in the second half of 2026.
The market has reacted to these announcements by moving the company's shares -0.46% to a price of $30.57. For more information, read the company's full 8-K submission here.
